Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2014
10/01/2014EP2783005A1 Recombinant serotype 5 (ac]5) adenoviral vectors
10/01/2014EP2782935A1 Anti-cd98 antibodies and methods of use thereof
10/01/2014EP2782928A1 Mutations of histone proteins associated with proliferative disorders
10/01/2014EP2782917A1 Thienopyrimidine inhibitors of atypical protein kinase c
10/01/2014EP2782903A1 Novel pyrrolidine derivatives as inhibitors of cathepsin
10/01/2014EP2782643A1 Androgen receptor ligands
10/01/2014EP2782600A1 Combination therapy using anti - cd20 antibody and human il-15
10/01/2014EP2782573A1 1,4- dihydropyridine derivatives with hsp modulating activity
10/01/2014EP2782570A1 Heterocyclic inhibitors of glutaminase
09/2014
09/30/2014US8846908 Tricyclic carbamate JAK inhibitors
09/30/2014US8846771 Compositions and methods of delivery of pharmacological agents
09/30/2014US8846734 Diazonamide analogs
09/30/2014US8846696 Purine derivatives
09/30/2014US8846686 Compounds useful as inhibitors of ATR kinase
09/30/2014US8846683 Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
09/30/2014US8846681 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
09/30/2014US8846653 Delta-tocotrienol treatment and prevention of pancreatic cancer
09/30/2014US8846602 Process for producing an injectable medicament preparation
09/30/2014US8846401 Promoters exhibiting endothelial cell specificity and methods of using same
09/30/2014US8846081 Liposome compositions and methods of use thereof
09/30/2014US8846026 Composition comprising immunogenic microparticles
09/30/2014CA2758820C Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
09/30/2014CA2669596C Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
09/30/2014CA2590935C Fc.gamma.riib-specific antibodies and methods of use thereof
09/25/2014WO2014153394A1 Cellular delivery of dna intercalating agents
09/25/2014WO2014153270A1 Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
09/25/2014WO2014153226A1 Arginine methyltransferase inhibitors and uses thereof
09/25/2014WO2014153208A1 Arginine methyltransferase inhibitors and uses thereof
09/25/2014WO2014153172A1 Pyrazole derivatives as prmt1 inhibitors and uses thereof
09/25/2014WO2014153164A1 Targeting agent antibody conjugates and uses thereof
09/25/2014WO2014153090A1 Pyrazole derivatives asprmt1 inhibitors and uses thereof
09/25/2014WO2014153023A1 5-bromo-indirubins
09/25/2014WO2014152932A1 Mirna for treating cancer and for use with adoptive immunotherapies
09/25/2014WO2014152725A1 S1p and/or atx modulating agents
09/25/2014WO2014152663A1 Crystalline forms of tyrosine kinase inhibitors and their salts
09/25/2014WO2014152444A1 Histone deacetylase inhibitors
09/25/2014WO2014152431A1 Stabilization of radioiodinated and astatinated pharmaceutials and imaging agents
09/25/2014WO2014152330A1 Arsenic-based treatment of cancers and inflammatory disorders
09/25/2014WO2014152215A1 SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
09/25/2014WO2014152199A1 Antibody drug conjugate (adc) purification
09/25/2014WO2014151988A1 Matrix metalloprotease (mmp) targeted agents for imaging and therapy
09/25/2014WO2014151945A1 Histone demethylase inhibitors
09/25/2014WO2014151900A1 Protein kinase c inhibitors and uses thereof
09/25/2014WO2014151866A1 Compositions and methods for diagnosis and treatment of hepatic cancers
09/25/2014WO2014151863A1 Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
09/25/2014WO2014151853A1 Methods of treating bladder cancer
09/25/2014WO2014151761A1 Novel choline kinase inhibitors
09/25/2014WO2014151682A1 Pyrimidine compounds as kinase inhibitors
09/25/2014WO2014151451A1 Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
09/25/2014WO2014151444A1 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
09/25/2014WO2014151258A1 Substituted pyridine derivatives useful as c-fms kinase inhibitors
09/25/2014WO2014151253A1 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma
09/25/2014WO2014151142A1 Modulators of methyl modifying enzymes, compositions and uses thereof
09/25/2014WO2014151030A1 Cell proliferation inhibitors and conjugates thereof
09/25/2014WO2014150996A1 Cancer treatment
09/25/2014WO2014150937A1 Antibody drug conjugates
09/25/2014WO2014150840A1 Methods of treating breast cancer
09/25/2014WO2014150829A1 Medicament for treatment of cancer, cardiovascular diseases and inflammation
09/25/2014WO2014150790A1 Pak1 inhibition for treatment of acute myeloid leukemia and myelodysplastic syndromes
09/25/2014WO2014150720A1 Compositions and methods relating to inhibiting cancer cell growth and/or proliferation
09/25/2014WO2014150646A1 Ido inhibitors
09/25/2014WO2014150252A1 Methods of treatment associated with the granulocyte colony-stimulating factor receptor
09/25/2014WO2014149001A1 STAPLING eIF4E INTERACTING PEPTIDES
09/25/2014WO2014148638A1 Aptamer to il-17 and use thereof
09/25/2014WO2014148574A1 Inhibition of production of il-2
09/25/2014WO2014148572A1 Cell metastasis or invasion inhibitor
09/25/2014WO2014148529A1 Double-stranded nucleic acid molecule, dna, vector, cancer cell proliferation inhibitor, and pharmaceutical product
09/25/2014WO2014147611A1 Quinolines derivatives as novel anticancer agents
09/25/2014WO2014147586A1 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
09/25/2014WO2014147203A1 3-heteroaryl substituted indazoles
09/25/2014WO2014147178A1 Hdac6 inhibitors and uses thereof
09/25/2014WO2014147144A1 Diaminoheteroaryl substituted indazoles
09/25/2014WO2014147095A1 Lipohillic oligonucleotide analogs
09/25/2014WO2014146778A1 Therapy involving antibodies against claudin 18.2 for treatment of cancer
09/25/2014WO2014146747A1 Piperazine derivatives as fasn inhibitors
09/25/2014WO2014146672A1 Therapy involving antibodies against claudin 18.2 for treatment of cancer
09/25/2014WO2014146575A1 Antibodies and methods for treating estrogen receptor-associated diseases
09/25/2014WO2014146493A1 Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146492A1 N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146490A1 Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146487A1 Anti-cell surface ectopic expression monoclonal antibody, preparation method and use thereof
09/25/2014WO2014146486A1 Three-level cyclic amine alk kinase inhibitor for treating cancer
09/25/2014WO2014146202A1 Bacteria for the prevention, treatment and diagnosis of breast cancer
09/25/2014US20140288023 Cyclodextrin-based polymers for therapeutics delivery
09/24/2014EP2781598A1 Nucleic acid molecule for inhibiting activity of rnai molecule
09/24/2014EP2781526A1 Bispecific anti-VEGF/anti-ANG-2 antibodies
09/24/2014EP2781523A1 Lipophilic oligonucleotide analogs
09/24/2014EP2781520A1 Three-ring pi3k and/or mtor inhibitor
09/24/2014EP2781517A1 Nitrogenated heterocyclic compound
09/24/2014EP2781223A1 Compositions comprising semaphorins for the treatment of angiogenesis related diseases
09/24/2014EP2780375A1 Binding molecules for bcma and cd3
09/24/2014EP2780374A1 Binding molecules for bcma and cd3
09/24/2014EP2780361A1 Conjugates of gm-csf and il-7, compositions and methods related thereto
09/24/2014EP2780342A1 Aminoquinazoline derivatives and their salts and methods of use
09/24/2014EP2780341A1 Kinase modulating compounds, compositions containing the same and use thereof
09/24/2014EP2780338A1 Uracil derivatives as axl and c-met kinase inhibitors
09/24/2014EP2780332A1 Morpholinyl benzotriazine for use in cancer therapy
09/24/2014EP2780331A1 Pharmaceutically active pyrazine derivatives
09/24/2014EP2780326A1 Method for inhibition of deubiquitinating activity
09/24/2014EP2780040A1 Methods of treating epidermal growth factor deletion mutant viii related disorders
1 ... 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ... 2211